Intercessor
Beloved of All
Novavax submitted its emergency use authorization on January 31, and there has been no meeting scheduled of the FDA's advisory committee.
By comparison, Pfizer/BioNTech's meeting was scheduled on December 10, 2020, after filing on November 20. Moderna's (MRNA) meeting was scheduled on December 17, 2020, after filing on November 30. Both vaccines have also now been fully approved for adult use as of January 2022.
J&J also followed a quick timeline, submitting on February 6, 2021 and a meeting scheduled on February 26. It's why Gostin is wary of the FDA's current pace.
"Whatever it is, there's some dynamic other than science going on," he said.
By comparison, Pfizer/BioNTech's meeting was scheduled on December 10, 2020, after filing on November 20. Moderna's (MRNA) meeting was scheduled on December 17, 2020, after filing on November 30. Both vaccines have also now been fully approved for adult use as of January 2022.
J&J also followed a quick timeline, submitting on February 6, 2021 and a meeting scheduled on February 26. It's why Gostin is wary of the FDA's current pace.
"Whatever it is, there's some dynamic other than science going on," he said.
FDA 'slow-walking' Novavax authorization: Expert
Novavax fans, investors and patients alike, are frustrated by FDA's delays in authorizing COVID-19 vaccine.
finance.yahoo.com